Table 2 MRRa for all-cause, cancer-specific and other-cause death among AML CML and myeloma patients, Sweden 2002–2009
AMLb MRR (95 % CI) | CMLc MRR (95 % CI) | Myeloma MRR (95 % CI) | |
|---|---|---|---|
All-cause death | |||
Comorbid disease | |||
No | 1.00 | 1.00 | 1.00 |
Yes | 1.39 (1.26–1.52) | 1.64 (1.34–2.01) | 1.40 (1.30–1.50) |
No. of comorbid diseases | |||
0 | 1.00 | 1.00 | 1.00 |
1 | 1.25 (1.12–1.38) | 1.41 (1.12–1.77) | 1.29 (1.19–1.40) |
2+ | 1.78 (1.57–2.02) | 2.22 (1.71–2.88) | 1.67 (1.51–1.85) |
Sex | |||
Men | 1.00 | 1.00 | 1.00 |
Women | 0.91 (0.84–1.00) | 0.83 (0.69–1.02) | 0.89 (0.83–0.95) |
Education level | |||
0–9 | 1.00 | 1.00 | 1.00 |
10–12 | 0.98 (0.89–1.09) | 1.09 (0.89–1.35) | 0.97 (0.89–1.04) |
> 12 | 0.80 (0.70–0.91) | 0.93 (0.70–1.25) | 0.83 (0.75–0.92) |
Cancer-specific death | |||
Comorbid disease | |||
No | 1.00 | 1.00 | 1.00 |
Yes | 1.27 (1.15–1.40) | 1.28 (0.96–1.70) | 1.17 (1.08–1.28) |
No. of comorbid diseases | |||
0 | 1.00 | 1.00 | 1.00 |
1 | 1.16 (1.04–1.29) | 1.12 (0.81–1.55) | 1.12 (1.02–1.23) |
2+ | 1.60 (1.39–1.83) | 1.66 (1.13–2.44) | 1.31 (1.15–1.48) |
Sex | |||
Men | 1.00 | 1.00 | 1.00 |
Women | 0.92 (0.84–1.01) | 0.91 (0.70–1.20) | 0.91 (0.84–0.99) |
Education level | |||
0–9 | 1.00 | 1.00 | 1.00 |
10–12 | 0.97 (0.87–1.08) | 1.19 (0.89–1.58) | 0.96 (0.88–1.06) |
> 12 | 0.80 (0.69–0.91) | 0.72 (0.46–1.12) | 0.87 (0.78–0.97) |
Other-cause death | |||
Comorbid disease | |||
No | 1.00 | 1.00 | 1.00 |
Yes | 2.64 (2.00–3.48) | 2.14 (1.60–2.85) | 2.22 (1.94–2.55) |
No. of comorbid diseases | |||
0 | 1.00 | 1.00 | 1.00 |
1 | 2.22 (1.64–3.01) | 1.80 (1.30–2.49) | 1.91 (1.64–2.23) |
2+ | 3.86 (2.72–5.47) | 2.98 (2.07–4.30) | 3.02 (2.53–3.62) |
Sex | |||
Men | 1.00 | 1.00 | 1.00 |
Women | 0.90 (0.69–1.16) | 0.76 (0.58–1.01) | 0.82 (0.72–0.94) |
Education level | |||
0–9 | 1.00 | 1.00 | 1.00 |
10–12 | 1.07 (0.79–1.43) | 1.00 (0.73–1.36) | 0.97 (0.83–1.13) |
> 12 | 0.85 (0.58–1.25) | 1.17 (0.80–1.73) | 0.72 (0.58–0.88) |